Search

Your search keyword '"Macgowan, G"' showing total 330 results
Start Over Author "Macgowan, G"
330 results on '"Macgowan, G"'

107. Poster session III * Friday 10 December 2010, 08:30-12:30

Author

Guldbrand, D., primary, Goetzsche, O., additional, Eika, B., additional, Watanabe, N., additional, Taniguchi, M., additional, Akagi, T., additional, Koide, N., additional, Sano, S., additional, Orbovic, B., additional, Obrenovic-Kircanski, B., additional, Ristic, S., additional, Soskic, L. J., additional, Alhabshan, F., additional, Jijeh, A., additional, Abo Remsh, H., additional, Alkhaldi, A., additional, Najm, H. K., additional, Gasior, Z., additional, Skowerski, M., additional, Kulach, A., additional, Szymanski, L., additional, Sosnowski, M., additional, Wang, M., additional, Siu, C. W., additional, Lee, K., additional, Yue, W. S., additional, Yan, G. H., additional, Lee, S., additional, Lau, C. P., additional, Tse, H. F., additional, O'connor, K., additional, Rosca, M., additional, Magne, J., additional, Romano, G., additional, Moonen, M., additional, Pierard, L. A., additional, Lancellotti, P., additional, Floria, M., additional, De Roy, L., additional, Blommaert, D., additional, Jamart, J., additional, Dormal, F., additional, Lacrosse, M., additional, Arsenescu Georgescu, C., additional, Mizariene, V., additional, Bucyte, S., additional, Bertasiute, A., additional, Pociute, E., additional, Zaliaduonyte-Peksiene, D., additional, Baronaite-Dudoniene, K., additional, Sileikiene, R., additional, Vaskelyte, J., additional, Jurkevicius, R., additional, Dencker, M., additional, Thorsson, O., additional, Karlsson, M. K., additional, Linden, C., additional, Wollmer, P., additional, Andersen, L. B., additional, Catalano, O., additional, Perotti, M. R., additional, Colombo, E., additional, De Giorgi, M., additional, Cattaneo, M., additional, Cobelli, F., additional, Priori, S. G., additional, Ober, C., additional, Iancu Adrian, I. A., additional, Andreea Parv, P. A., additional, Cadis Horatiu, C. H., additional, Ober Mihai, O. M., additional, Chmielecki, M., additional, Fijalkowski, M., additional, Galaska, R., additional, Dubaniewicz, W., additional, Lewicki, L., additional, Targonski, R., additional, Ciecwierz, D., additional, Puchalski, W., additional, Koprowski, A., additional, Rynkiewicz, A., additional, Hristova, K., additional, La Gerche, A., additional, Katova, T. Z., additional, Kostova, V., additional, Simova, Y., additional, Kempny, A., additional, Diller, G. P., additional, Orwat, S., additional, Kaleschke, G., additional, Kerckhoff, G., additional, Schmidt, R., additional, Radke, R. M., additional, Baumgartner, H., additional, Smarz, K., additional, Zaborska, B., additional, Jaxa-Chamiec, T., additional, Maciejewski, P., additional, Budaj, A., additional, Kiotsekoglou, A., additional, Govind, S. C., additional, Gadiyaram, V., additional, Moggridge, J. C., additional, Govindan, M., additional, Gopal, A. S., additional, Ramesh, S. S., additional, Brodin, L. A., additional, Saha, S. K., additional, Ramzy, I. S., additional, Lindqvist, P., additional, Lam, Y. Y., additional, Duncan, A. M., additional, Henein, M. Y., additional, Craciunescu, I. S., additional, Serban, M., additional, Iancu, M., additional, Revnic, C., additional, Popescu, B. A., additional, Alexandru, D., additional, Rogoz, D., additional, Uscatescu, V., additional, Ginghina, C., additional, Careri, G., additional, Di Monaco, A., additional, Nerla, R., additional, Tarzia, P., additional, Lamendola, P., additional, Sestito, A., additional, Lanza, G. A., additional, Crea, F., additional, Giannini, F., additional, Pinamonti, B., additional, Santangelo, S., additional, Perkan, A., additional, Vitrella, G., additional, Rakar, S., additional, Merlo, M., additional, Della Grazia, E., additional, Salvi, A., additional, Sinagra, G., additional, Scislo, P., additional, Kochanowski, J., additional, Piatkowski, R., additional, Roik, M., additional, Postula, M., additional, Opolski, G., additional, Castillo, J., additional, Herszkowicz, N., additional, Ferreira, C., additional, Lonnebakken, M. T., additional, Staal, E. M., additional, Nordrehaug, J. E., additional, Gerdts, E., additional, Przewlocka-Kosmala, M., additional, Orda, A., additional, Karolko, B., additional, Bajraktari, G., additional, Gustafsson, U., additional, Holmgren, A., additional, Frattini, S., additional, Faggiano, P., additional, Zilioli, V., additional, Locantore, E., additional, Longhi, S., additional, Bellandi, F., additional, Faden, G., additional, Triggiani, M., additional, Dei Cas, L., additional, Seo, S. M., additional, Jung, H. O., additional, An, S. H., additional, Jung, S. Y., additional, Park, C. S., additional, Jeon, H. K., additional, Youn, H. J., additional, Chung, W. B., additional, Kim, J. H., additional, Uhm, J. S., additional, Mampuya, W., additional, Brochu, M. C., additional, Do, D. H., additional, Essadiqi, B., additional, Farand, P., additional, Lepage, S., additional, Daly, M. J., additional, Monaghan, M., additional, Hamilton, A., additional, Lockhart, C., additional, Kodoth, V., additional, Maguire, C., additional, Morton, A., additional, Manoharan, G., additional, Spence, M. S., additional, Streb, W., additional, Mitrega, K., additional, Nowak, J., additional, Duszanska, A., additional, Szulik, M., additional, Kalinowski, M., additional, Kukulski, T., additional, Kalarus, Z., additional, Calvo Iglesias, F. E., additional, Solla-Ruiz, I., additional, Villanueva-Benito, I., additional, Paredes-Galan, E., additional, Bravo-Amaro, M., additional, Iniguez-Romo, A., additional, Yildirimturk, O., additional, Helvacioglu, F. F., additional, Tayyareci, Y., additional, Yurdakul, S., additional, Demiroglu, I. C., additional, Aytekin, S., additional, Enache, R., additional, Piazza, R., additional, Muraru, D., additional, Roman-Pognuz, A., additional, Calin, A., additional, Leiballi, E., additional, Antonini-Canterin, F., additional, Nicolosi, G. L., additional, Ridard, C., additional, Bellouin, A., additional, Thebault, C., additional, Laurent, M., additional, Donal, E., additional, Sutandar, A., additional, Siswanto, B. B., additional, Irmalita, I., additional, Harimurti, G., additional, Saxena, A., additional, Ramakrishnan, S., additional, Roy, A., additional, Krishnan, A., additional, Misra, P., additional, Bhargava, B., additional, Poole-Wilson, P. A., additional, Loegstrup, B. B., additional, Andersen, H. R., additional, Poulsen, S. H., additional, Klaaborg, K. E., additional, Egeblad, H. E., additional, Gu, X., additional, Gu, X. Y., additional, He, Y. H., additional, Li, Z. A., additional, Han, J. C., additional, Chen, J., additional, Mansencal, N., additional, Mitry, E., additional, Rougier, P., additional, Dubourg, O., additional, Villarraga, H., additional, Adjei-Twum, K., additional, Cudjoe, T. K. M., additional, Clavell, A., additional, Schears, R. M., additional, Cabrera Bueno, F., additional, Molina Mora, M. J., additional, Fernandez Pastor, J., additional, Linde Estrella, A., additional, Pena Hernandez, J. L., additional, Isasti Aizpurua, G., additional, Carrasco Chinchilla, F., additional, Barrera Cordero, A., additional, Alzueta Rodriguez, F. J., additional, De Teresa Galvan, E., additional, Gaetano Contegiacomo, G. C., additional, Francesco Pollice, F. P., additional, Paolo Pollice, P. P., additional, Kontos, M. C., additional, Shin, D. H., additional, Yoo, S. Y., additional, Lee, C. K., additional, Jang, J. K., additional, Jung, S. I., additional, Song, S. I., additional, Seo, S. I., additional, Cheong, S. S., additional, Peteiro, J., additional, Perez-Perez, A., additional, Bouzas-Mosquera, A., additional, Pineiro, M., additional, Pazos, P., additional, Campo, R., additional, Castro-Beiras, A., additional, Gaibazzi, N., additional, Rigo, F., additional, Sartorio, D., additional, Reverberi, C., additional, Sitia, S., additional, Tomasoni, L., additional, Gianturco, L., additional, Ghio, L., additional, Stella, D., additional, Greco, P., additional, De Gennaro Colonna, V., additional, Turiel, M., additional, Cicala, S., additional, Magagnin, V., additional, Caiani, E., additional, Kyrzopoulos, S., additional, Tsiapras, D., additional, Domproglou, G., additional, Avramidou, E., additional, Voudris, V., additional, Wierzbowska-Drabik, K., additional, Lipiec, P., additional, Chrzanowski, L., additional, Roszczyk, N., additional, Kupczynska, K., additional, Kasprzak, J. D., additional, Sachpekidis, V., additional, Bhan, A., additional, Gianstefani, S., additional, Reiken, J., additional, Paul, M., additional, Pearson, P., additional, Harries, D., additional, Monaghan, M. J., additional, Dale, K., additional, Stoylen, A., additional, Kodali, V., additional, Toole, R., additional, Raju, P., additional, Mcintosh, R. A., additional, Silberbauer, J., additional, Baumann, O., additional, Patel, N. R., additional, Sulke, N., additional, Trivedi, U., additional, Hyde, J., additional, Venn, G., additional, Lloyd, G., additional, Wejner-Mik, P., additional, Wierzbowska, K., additional, Lowenstein, J. A., additional, Caniggia, C., additional, Garcia, A., additional, Amor, M., additional, Casso, N., additional, Lowenstein Haber, D., additional, Porley, C., additional, Zambrana, G., additional, Daru, V., additional, Deljanin Ilic, M., additional, Ilic, S., additional, Kalimanovska Ostric, D., additional, Stoickov, V., additional, Zdravkovic, M., additional, Paraskevaidis, I., additional, Ikonomidis, I., additional, Parissis, J., additional, Papadopoulos, C., additional, Stasinos, V., additional, Bistola, V., additional, Anastasiou-Nana, M., additional, Gudin Uriel, M., additional, Balaguer Malfagon, J. R., additional, Perez Bosca, J. L., additional, Ridocci Soriano, F., additional, Martinez Alzamora, N., additional, Paya Serrano, R., additional, Ciampi, Q., additional, Pratali, L., additional, Della Porta, M., additional, Petruzziello, B., additional, Villari, B., additional, Picano, E., additional, Sicari, R., additional, Rosner, A., additional, Avenarius, D., additional, Malm, S., additional, Iqbal, A., additional, Baltabaeva, A., additional, Sutherland, G. R., additional, Bijnens, B., additional, Myrmel, T., additional, Andersen, M., additional, Gustafsson, F., additional, Secher, N. H., additional, Brassard, P., additional, Jensen, A. S., additional, Hassager, C., additional, Madsen, P. L., additional, Moller, J. E., additional, Coutu, M., additional, Greentree, D., additional, Normandin, D., additional, Brun, H., additional, Dipchand, A., additional, Koopman, L., additional, Fackoury, C. T., additional, Truong, S., additional, Manlhiot, C., additional, Mertens, L., additional, Baroni, M., additional, Mariani, M., additional, Chabane, H. K., additional, Berti, S., additional, Ripoli, A., additional, Storti, S., additional, Glauber, M., additional, Scopelliti, P. A., additional, Antongiovanni, G. B., additional, Personeni, D., additional, Saino, A., additional, Tespili, M., additional, Jung, P., additional, Mueller, M., additional, Jander, F., additional, Sohn, H. Y., additional, Rieber, J., additional, Schneider, P., additional, Klauss, V., additional, Agricola, E., additional, Slavich, M., additional, Stella, S., additional, Ancona, M., additional, Oppizzi, M., additional, Bertoglio, L., additional, Melissano, G., additional, Margonato, A., additional, Chiesa, R., additional, Cejudo Diaz Del Campo, L., additional, Mesa Rubio, D., additional, Ruiz Ortiz, M., additional, Delgado Ortega, M., additional, Villanueva Fernandez, E., additional, Lopez Aguilera, J., additional, Toledano Delgado, F., additional, Pan Alvarez-Ossorio, M., additional, Suarez De Lezo Cruz Conde, J., additional, Lafuente, M., additional, Butz, T., additional, Meissner, A., additional, Lang, C. N., additional, Prull, M. W., additional, Plehn, G., additional, Trappe, H. J., additional, Nair, S. V., additional, Lee, L., additional, Mcleod, I., additional, Whyte, G., additional, Shrimpton, J., additional, Hildick Smith, D., additional, James, P. R., additional, Slikkerveer, J., additional, Appelman, Y. E. A., additional, Veen, G., additional, Porter, T. R., additional, Kamp, O., additional, Colonna, P., additional, Ten Cate, F. J., additional, Bokor, D., additional, Daponte, A., additional, Cocciolo, M., additional, Bona, M., additional, Sacchi, S., additional, Becher, H., additional, Chai, S. C., additional, Tan, P. J., additional, Goh, Y. S., additional, Ong, S. H., additional, Chow, J., additional, Lee, L. L., additional, Goh, P. P., additional, Tong, K. L., additional, Kakihara, R., additional, Naruse, C., additional, Hironaka, H., additional, Tsuzuku, T., additional, Ozawa, K., additional, Tomaszuk-Kazberuk, A., additional, Sobkowicz, B., additional, Malyszko, J., additional, Malyszko, J. S., additional, Sawicki, R., additional, Hirnle, T., additional, Dobrzycki, S., additional, Mysliwiec, M., additional, Musial, W. J., additional, Mathias, W., additional, Kowatsch, I., additional, Saroute, A. L. R., additional, Osorio, A. F. F., additional, Sbano, J. C. N., additional, Ramires, J. A. F., additional, Tsutsui, J. M., additional, Sakata, K., additional, Ito, H., additional, Ishii, K., additional, Sakuma, T., additional, Iwakura, K., additional, Yoshino, H., additional, Yoshikawa, J., additional, Shahgaldi, K., additional, Lopez, A., additional, Fernstrom, B., additional, Sahlen, A., additional, Winter, R., additional, Kovalova, S., additional, Necas, J., additional, Amundsen, B. H., additional, Jasaityte, R., additional, Kiss, G., additional, Barbosa, D., additional, D'hooge, J., additional, Torp, H., additional, Szmigielski, C. A., additional, Newton, J. D., additional, Rajpoot, K., additional, Noble, J. A., additional, Kerber, R., additional, Koopman, L. P., additional, Slorach, C., additional, Chahal, N., additional, Hui, W., additional, Sarkola, T., additional, Bradley, T. J., additional, Jaeggi, E. T., additional, Mccrindle, B. W., additional, Staron, A., additional, Jasinski, M., additional, Wos, S., additional, Sengupta, P., additional, Hayat, D., additional, Kloeckner, M., additional, Nahum, J., additional, Dussault, C., additional, Dubois Rande, J. L., additional, Gueret, P., additional, Lim, P., additional, King, G. J., additional, Brown, A., additional, Ho, E., additional, Amuntaser, I., additional, Bennet, K., additional, Mc Elhome, N., additional, Murphy, R. T., additional, Cooper, R. M., additional, Somauroo, J. D., additional, Shave, R. E., additional, Williams, K. L., additional, Forster, J., additional, George, C., additional, Bett, T., additional, George, K. P., additional, D'andrea, A., additional, Riegler, L., additional, Cocchia, R., additional, Golia, E., additional, Gravino, R., additional, Salerno, G., additional, Citro, R., additional, Caso, P. I. O., additional, Bossone, E., additional, Calabro', R., additional, Crispi, F., additional, Figueras, F., additional, Bartrons, J., additional, Eixarch, E., additional, Le Noble, F., additional, Ahmed, A., additional, Gratacos, E., additional, Shang, Q., additional, Yip, W. K., additional, Tam, L. S., additional, Zhang, Q., additional, Li, C. M., additional, Wang, T., additional, Ma, C. Y., additional, Li, K. M., additional, Yu, C. M., additional, Dahlslett, T., additional, Helland, I., additional, Edvardsen, T., additional, Skulstad, H., additional, Magda, L. S., additional, Florescu, M., additional, Ciobanu, A., additional, Dulgheru, R., additional, Mincu, R., additional, Vinereanu, D., additional, Luckie, M., additional, Chacko, S., additional, Nair, S., additional, Mamas, M., additional, Khattar, R. S., additional, El-Omar, M., additional, Kuch-Wocial, A., additional, Pruszczyk, P., additional, Szulc, M., additional, Styczynski, G., additional, Sinski, M., additional, Kaczynska, A., additional, Vela, Z., additional, Haliti, E., additional, Hyseni, V., additional, Olloni, R., additional, Rexhepaj, N., additional, Elezi, S., additional, Onaindia, J. J., additional, Quintana, O., additional, Cacicedo, A., additional, Velasco, S., additional, Alarcon, J. J., additional, Morillas, M., additional, Rumoroso, J. R., additional, Zumalde, J., additional, Lekuona, I., additional, Laraudogoitia Zaldumbide, E., additional, Poniku, A., additional, Ahmeti, A., additional, Duncan, R. F., additional, Mccomb, J. M., additional, Pemberton, J., additional, Lord, S. W., additional, Leong, D., additional, Plummer, C., additional, Macgowan, G., additional, Grubb, N., additional, Leung, M., additional, Kenny, A., additional, Prinz, C., additional, Voigt, J. U., additional, Zaidi, A., additional, Heatley, M., additional, Abildstrom, S. Z., additional, Hvelplund, A., additional, Berning, J., additional, Govind, S., additional, Brodin, L., additional, Gopal, A., additional, Castaldi, B., additional, Di Salvo, G., additional, Santoro, G., additional, Gaio, G., additional, Palladino, M. T., additional, Iacono, C., additional, Pacileo, G., additional, Russo, M. G., additional, Calabro, R., additional, Wang, Y. S., additional, Dong, L. L., additional, Shu, X. H., additional, Pan, C. Z., additional, Zhou, D. X., additional, Sen, T., additional, Tufekcioglu, O., additional, Ozdemir, M., additional, Tuncez, A., additional, Uygur, B., additional, Golbasi, Z., additional, Kisacik, H., additional, Delfino, L., additional, De Leo, F. D., additional, Chiappa, L. C., additional, Abdel Ghani, B., additional, Schiavina, R., additional, Salvade, P., additional, Morganti, A., additional, Bedogni, F., additional, Mahia, P., additional, Gutierrez, L., additional, Pineda, V., additional, Garcia, B., additional, Otaegui, I., additional, Rodriguez, J. F., additional, Gonzalez, M. T., additional, Descalzo, M., additional, Evangelista, A., additional, Garcia-Dorado, D., additional, Bruin De- Bon, H. A. C. M., additional, Van Den Brink, R. B. A., additional, Surie, S., additional, Bresser, P., additional, Vleugels, J., additional, Eckmann, H. M., additional, Samson, D. A., additional, Bouma, B. J., additional, Dedobbeleer, C., additional, Antoine, M., additional, Remmelink, M., additional, Unger, P., additional, Roosens, B., additional, Hmila, I., additional, Hernot, S., additional, Droogmans, S., additional, Van Camp, G., additional, Lahoutte, T., additional, Muyldermans, S., additional, Cosyns, B., additional, Feltes, G., additional, Serra, V., additional, Azevedo, O., additional, Barbado, J., additional, Herrera, J., additional, Rivera, A., additional, Paniagua, J., additional, Valverde, V., additional, Torras, J., additional, Arriba, G., additional, Christodoulides, T., additional, Ioannides, M., additional, Simamonian, K., additional, Yiangou, K., additional, Myrianthefs, M., additional, Nicolaides, E., additional, Pandolfo, M., additional, Kleijn, S. A., additional, Aly, M. F. A. A., additional, Terwee, C. B., additional, Van Rossum, A. C., additional, Delgado, V., additional, Shanks, M., additional, Siebelink, H. M., additional, Sieders, A., additional, Lamb, H., additional, Ajmone Marsan, N., additional, Westenberg, J., additional, De Roos, A., additional, Schuijf, J. D., additional, Bax, J. J., additional, Anwar, A. M., additional, Nosir, Y., additional, Chamsi-Pasha, H., additional, Tschernich, H. D., additional, Seeburger, J., additional, Borger, M., additional, Mukherjee, C., additional, Mohr, F. W., additional, Ender, J., additional, Obase, K., additional, Okura, H., additional, Yamada, R., additional, Miyamoto, Y., additional, Saito, K., additional, Imai, K., additional, Hayashida, A., additional, and Yoshida, K., additional

Published
2010
Full Text
View/download PDF

123. Effects of afterload on regional left ventricular torsion

Author

MacGowan, G. A., primary, Burkhoff, D., additional, Rogers, W. J., additional, Salvador, D., additional, Azhari, H., additional, Hees, P. S., additional, Zweier, J. L., additional, Halperin, H. R., additional, Siu, C. O., additional, Lima, J. A.C., additional, Weiss, J. L., additional, and Shapiro, E. P., additional

Published
1996
Full Text
View/download PDF

124. Irish cardiac society

Author

Crowley, J. J., primary, Naughton, M. A., additional, King, G., additional, Maurer, J., additional, Quigley, P. J., additional, McNeill, A. J., additional, Fioretti, P. M., additional, Salustri, A., additional, Pozzolu, M. M. A., additional, Broekema, C. C., additional, Elsaid, E. M., additional, Roelandt, J. R., additional, Garadaha, M. T., additional, Algazzar, A. H., additional, Dayem, H., additional, Crean, P., additional, Cairn, H. A. M., additional, Blanchard, D. G., additional, Rivera, I., additional, Peterson, K. L., additional, Buchbinder, M., additional, Dittrick, H., additional, MacGowan, G. A., additional, Herlihy, M., additional, O’Brien, E., additional, Horgan, J. H., additional, Purvis, J. A., additional, Roberts, M. J. D., additional, Cave, M., additional, Webb, S. W., additional, Campbell, N. P. S., additional, Patterson, G. C., additional, Wilson, C. M., additional, Khan, M. M., additional, Adgey, A. A. J., additional, McClements, D. M., additional, Cochrane, D., additional, Jauch, W., additional, Scriven, A. J., additional, Cobbe, S. M., additional, Sheehan, R., additional, McAdam, B., additional, Foley, D., additional, Kinsella, A., additional, Walsh, N., additional, White, U., additional, Gearty, G., additional, Walsh, M., additional, Rush, R., additional, Cooper, A., additional, Crowe, P., additional, Young, I. S., additional, Trimble, E. R., additional, King., G., additional, Elgaylani, N., additional, Hamilton, D., additional, McAleer, B., additional, Ruane, B., additional, Dalton, G., additional, Varma, M. P. S., additional, Sheahan, R., additional, Freyne, P. J., additional, Kidney, D. D., additional, Gearty, G. F., additional, Ryan, M., additional, Cooke, T., additional, Robinson, K., additional, Younger, K., additional, Feely, J., additional, Graham, I., additional, Hurley, J., additional, McDonagh, P. M., additional, White, M., additional, Phelan, D., additional, Luke, D., additional, McGovem, E., additional, Clements, B., additional, Lonergan, M., additional, Daly, L., additional, Wood, A. E., additional, Craig, B., additional, Mulholland, D., additional, Gladstone, D., additional, O’Kane, H., additional, Cleland, J., additional, Rajan, L., additional, Murphy, S., additional, Fielding, J., additional, Smith, E., additional, Pahy, G., additional, Deb, B., additional, Elliott, J., additional, Maguire, C., additional, Wilson, M., additional, McEneaney, D., additional, Adgey, J., additional, Anderson, J., additional, Gibney, M., additional, Primrose, E. D., additional, Savage, J. M., additional, Cran, G. W., additional, Mulholland, H., additional, Thomas, P. J., additional, Donnelly, M. D. I., additional, Kenny, R. A., additional, Traynor, G., additional, Burges, L., additional, Wilson, C., additional, Gladstone, D. J., additional, Walsh, K., additional, Sreeram, N. S., additional, Franks, R., additional, Arnold, R., additional, Gaylani, N. EL, additional, Jaison, T. N., additional, McGovern, E., additional, O’Sullivan, J., additional, Wren, C., additional, Bain, H. H., additional, Hunter, S., additional, O’Donnell, A. F., additional, Jayakrishnan, A. G., additional, Desai, J., additional, and Forsyth, A. T., additional

Published
1992
Full Text
View/download PDF

128. Noninvasive measurement of shortening in the fiber and cross-fiber directions in the normal human left ventricle and in idiopathic dilated cardiomyopathy

Author

Macgowan, G. A., Shapiro, E. P., Haim Azhari, Siu, C. O., Hees, P. S., Hutchins, G. M., Weiss, J. L., and Rademakers, F. E.

Subjects
Human medicine
Abstract

Background Studies in anesthetized dogs have shown that myocardial fibers shorten approximate to 8%. However, in the endocardium, shortening occurs to a much greater extent at 90 degrees to the fiber orientation (''cross-fiber shortening'') than it does along the fiber direction. The purpose of this study was to estimate the extent of fiber and cross-fiber shortening in the normal human left ventricle and in patients with idiopathic dilated cardiomyopathy (IDC). Methods and Results Ten normal subjects and nine patient with IDC were imaged with magnetic resonance tissue tagging. Finite strain analysis was used to calculate endocardial and epicardial shortening in the fiber and cross-fiber directions using anatomic fiber angles from representative autopsy specimens as references. Anatomic fiber angles were not different between normal subjects and IDC patients. Epicardial fiber strain was -0.14+/-0.01 in normal subjects and -0.08+/-0.01 in IDC patients (P

132. latrogenic pulmonary artery pseudoaneurysm: images from different modalities.

Author

McQueen, A. S., Mitchell, I., Muller, M., MacGowan, G., and Corris, P.

Subjects
PULMONARY artery, PULMONARY blood vessels, MAGNETIC resonance imaging, MEDICAL research, MORTALITY
Abstract

The article presents a pulmonary artery hypertension examination conducted to a 68-year-old woman. To investigate the cause of this disease, a CT pulmonary angiogram, a cardiac MRI, and a catheter angiogram were performed, its images are showed. It infers that most ruptures of the right pulmonary artery occur in the middle or lower lobe branches and carry a mortality rate up to 50%. Treatment using transcatheter embolisation is recommended.

Published
2008
Full Text
View/download PDF

135. 238th ENMC International Workshop: Updating management recommendations of cardiac dystrophinopathy Hoofddorp, The Netherlands, 30 November-2 December 2018

Author

John P. Bourke, Michela Guglieri, Denis Duboc, Annemieke Aartsma-Rus, Alykhan Bandali, Neil Bennett, Bjorn Cools, Linda Cripe, Imelda de Groot, Sven Dittrich, Anca Florian, Pat Furlong, Nathalie Goemans, Kan Hor, Frank van Leperen, Guy MacGowan, Elizabeth McNally, Elena Pegoraro, Luisa Politano, Marie Sediva, Veronika Stara, Janneke Timmermans, Elizabeth Vroom, Karim Wahbi, Bourke, Jp, Guglieri, M, Duboc, D, Aartsma-Rus, A, Bandali, A, Bennett, N, Cools, B, Cripe, L, de Groot, I, Dittrich, S, Florian, A, Furlong, P, Goemans, N, Hor, K, van Leperen, F, Macgowan, G, Mcnally, E, Pegoraro, E, Politano, L, Sediva, M, Stara, V, Timmermans, J, Vroom, E, and Wahbi, K.

Subjects
medicine.medical_specialty, business.industry, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], MEDLINE, Heart failure drugs, Cardiac dystrophinopathy, Device therapy, Neurology, Pediatrics, Perinatology and Child Health, medicine, Cardiac imaging, Medical physics, Neurology (clinical), business, Genetics (clinical)
Abstract

Contains fulltext : 209413.pdf (Publisher’s version ) (Closed access)

Published
2019

136. Prognostic value of repeated peak oxygen uptake measurements in patients with a left ventricular assist device.

Author

Nielsen WH, Szymanski MK, Mirza KK, Van Laake LW, Schmidt T, Brahmbhatt DH, Billia F, Hsu S, MacGowan G, Jakovljevic DG, Agostoni P, Trombara F, Jorde UP, Rochlani Y, Vandersmissen K, Reiss N, Russell SD, Meyns B, and Gustafsson F

Subjects
Humans, Male, Female, Prognosis, Middle Aged, Follow-Up Studies, Survival Rate trends, Retrospective Studies, Adult, Heart-Assist Devices, Heart Failure physiopathology, Heart Failure therapy, Heart Failure mortality, Oxygen Consumption physiology, Exercise Test
Abstract

Background: Peak oxygen uptake (pVO 2 ) predicts mortality in patients with heart failure on left ventricular assist device (LVAD) support. This follow-up of the PRO-VAD study examines the prognostic value of repeated pVO 2 measurements during long-term follow-up., Methods: This multicenter follow-up study included patients from the original PRO-VAD cohort who performed a cardiopulmonary exercise test (CPET) twice. Patients were categorized into 4 groups based on pVO 2 levels at the 2 CPETs: low at both tests, low at the first and high at the second test, high at the first and low at the second test, and high at both tests. Low pVO 2 was defined as ≤14 ml/kg/min (or ≤12 ml/kg/min if beta-blocker tolerant), while values above these thresholds were considered high. Survival outcomes were analyzed using the Kaplan-Meier method and cause-specific Cox analysis., Results: The study included 152 patients with repeated CPETs at approximately 6 and 12 months following LVAD implantation. The cohort showed slight but significant pVO 2 improvement (median change: 0.4 ml/kg/min, p = 0.04). Persistently high pVO 2 (76 patients) was associated with a 5-fold reduction in mortality hazard (hazard ratio [HR] 0.20, p = 0.002), compared with persistently low pVO 2 (46 patients). Improvement from low to high pVO 2 (21 patients) displayed similar benefits (HR 0.21, p = 0.02)., Conclusions: pVO 2 measurements remain predictive of mortality upon reiteration in patients with LVAD, with changes in pVO 2 providing additional prognostic value in identifying patients with an excellent outcome on ongoing LVAD support and in identifying patients requiring further interventions., (Copyright © 2024 International Society for the Heart and Lung Transplantation. All rights reserved.)

Published
2025
Full Text
View/download PDF

139. British societies guideline on the management of emergencies in implantable left ventricular assist device recipients in transplant centres.

Author

Akhtar W, Baston VR, Berman M, Bhagra S, Chue C, Deakin CD, Dalzell JR, Dunning J, Dunning J, Gardner RS, Kiff K, Kore S, Lim S, MacGowan G, Naldrett I, Ostermann M, Pinto S, Pettit S, Gil FR, Rosenberg A, Rubino A, Sayeed R, Sequeira J, Swanson N, Tsui S, Walker C, Webb S, Woods A, Ventkateswaran R, and Bowles CT

Subjects
Humans, Emergencies, Heart Transplantation, Heart-Assist Devices, Clinical Deterioration, Heart Failure therapy
Abstract

An implantable left ventricular assist device (LVAD) is indicated as a bridge to transplantation or recovery in the United Kingdom (UK). The mechanism of action of the LVAD results in a unique state of haemodynamic stability with diminished arterial pulsatility. The clinical assessment of an LVAD recipient can be challenging because non-invasive blood pressure, pulse and oxygen saturation measurements may be hard to obtain. As a result of this unusual situation and complex interplay between the device and the native circulation, resuscitation of LVAD recipients requires bespoke guidelines. Through collaboration with key UK stakeholders, we assessed the current evidence base and developed guidelines for the recognition of clinical deterioration, inadequate circulation and time-critical interventions. Such guidelines, intended for use in transplant centres, are designed to be deployed by those providing immediate care of LVAD patients under conditions of precipitous clinical deterioration. In summary, the Joint British Societies and Transplant Centres LVAD Working Group present the UK guideline on management of emergencies in implantable LVAD recipients for use in advanced heart failure centres. These recommendations have been made with a UK resuscitation focus but are widely applicable to professionals regularly managing patients with implantable LVADs., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

140. Sacubitril/valsartan reverses cardiac structure and function in experimental model of hypertension-induced hypertrophic cardiomyopathy.

Author

Jeremic J, Govoruskina N, Bradic J, Milosavljevic I, Srejovic I, Zivkovic V, Jeremic N, Nikolic Turnic T, Tanaskovic I, Bolevich S, Jakovljevic V, Bolevich S, Zivanovic MN, Okwose N, Seklic D, Milivojevic N, Grujic J, Velicki L, MacGowan G, Jakovljevic DG, and Filipovic N

Subjects
Rats, Animals, Tetrazoles pharmacology, Tetrazoles metabolism, Tetrazoles therapeutic use, Valsartan pharmacology, Valsartan metabolism, Valsartan therapeutic use, Myocytes, Cardiac metabolism, Rats, Inbred WKY, Models, Theoretical, Hypertension, Cardiomyopathy, Hypertrophic drug therapy
Abstract

This study evaluated the effect of sacubtril/valsartan on cardiac remodeling, molecular and cellular adaptations in experimental (rat) model of hypertension-induced hypertrophic cardiomyopathy. Thirty Wistar Kyoto rats, 10 healthy (control) and 20 rats with confirmed hypertension-induced hypertrophic cardiomyopathy (HpCM), were used for this study. The HpCM group was further subdivided into untreated and sacubitril/valsartan-treated groups. Myocardial structure and function were assessed using echocardiography, Langendorff's isolated heart experiment, blood sampling and qualitative polymerase chain reaction. Echocardiographic examinations revealed protective effects of sacubitril/valsartan by improving left ventricular internal diameter in systole and diastole and fractional shortening. Additionally, sacubitril/valsartan treatment decreased systolic and diastolic blood pressures in comparison with untreated hypertensive rats. Moreover, sacubitril/valsartan treatment reduced oxidative stress and apoptosis (reduced expression of Bax and Cas9 genes) compared to untreated rats. There was a regular histomorphology of cardiomyocytes, interstitium, and blood vessels in treated rats compared to untreated HpCM rats which expressed hypertrophic cardiomyocytes, with polymorphic nuclei, prominent nucleoli and moderately dilated interstitium. In experimental model of hypertension-induced hypertrophic cardiomyopathy, sacubitril/valsartan treatment led to improved cardiac structure, haemodynamic performance, and reduced oxidative stress and apoptosis. Sacubitril/valsartan thus presents as a potential therapeutic strategy resulted in hypertension-induced hypertrophic cardiomyopathy., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2023
Full Text
View/download PDF

141. Habitual physical activity levels of adults with heart failure: systematic review and meta-analysis.

Author

Jordan C, Charman SJ, Batterham AM, Flynn D, Houghton D, Errington L, MacGowan G, and Avery L

Subjects
Humans, Adult, Exercise, Quality of Life, Heart Failure diagnosis, Heart Failure therapy
Abstract

Objective: To conduct a systematic review and meta-analysis to quantify habitual physical activity (PA) levels of patients with heart failure (HF) and assess the quality of reporting of device-assessed PA., Methods: Eight electronic databases were searched up to 17 November 2021. Data on the study and population characteristics, method of PA measurement and PA metrics were extracted. A random-effects meta-analysis (restricted maximum likelihood with Knapp-Hartung SE adjustment) was conducted., Results: Seventy-five studies were included in the review (n=7775 patients with HF). Meta-analysis was restricted to mean steps per day, encompassing 27 studies (n=1720 patients with HF). Pooled mean steps per day were 5040 (95% CI: 4272 to 5807). The 95% prediction interval for mean steps per day in a future study was 1262 to 8817. Meta-regression at the study level revealed that a 10-year increment in the mean age of patients was associated with 1121 fewer steps per day (95% CI: 258 to 1984)., Conclusions: Patients with HF are a low-active population. These findings have implications for the way in which PA is targeted in patients with HF, and interventions should focus on addressing the age-related decline observed as well as increasing PA to improve HF symptoms and quality of life., Prospero Registration Number: CRD42020167786., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

143. A national pilot of donation after circulatory death (DCD) heart transplantation within the United Kingdom.

Author

Messer S, Rushton S, Simmonds L, Macklam D, Husain M, Jothidasan A, Large S, Tsui S, Kaul P, Baxter J, Osman M, Mehta V, Russell D, Stock U, Dunning J, Saez DG, Venkateswaran R, Curry P, Ayton L, Mukadam M, Mascaro J, Simmonds J, Macgowan G, Clark S, Jungschleger J, Reinhardt Z, Quigley R, Speed J, Parameshwar J, Jenkins D, Watson S, Marley F, Ali A, Gardiner D, Rubino A, Whitney J, Beale S, Slater C, Currie I, Armstrong L, Foley J, Ryan M, Gibson S, Quinn K, Macleod AM, Spence S, Watson CJE, Catarino P, Clarkson A, Forsythe J, Manas D, and Berman M

Subjects
Adult, Humans, Child, Tissue Donors, Retrospective Studies, Pilot Projects, Brain Death, United Kingdom epidemiology, Graft Survival, Death, Heart Transplantation, Tissue and Organ Procurement
Abstract

Background: The United Kingdom (UK) was one of the first countries to pioneer heart transplantation from donation after circulatory death (DCD) donors. To facilitate equity of access to DCD hearts by all UK heart transplant centers and expand the retrieval zone nationwide, a Joint Innovation Fund (JIF) pilot was provided by NHS Blood and Transplant (NHSBT) and NHS England (NHSE). The activity and outcomes of this national DCD heart pilot program are reported., Methods: This is a national multi-center, retrospective cohort study examining early outcomes of DCD heart transplants performed across 7 heart transplant centers, adult and pediatric, throughout the UK. Hearts were retrieved using the direct procurement and perfusion (DPP) technique by 3 specialist retrieval teams trained in ex-situ normothermic machine perfusion. Outcomes were compared against DCD heart transplants before the national pilot era and against contemporaneous donation after brain death (DBD) heart transplants, and analyzed using Kaplan-Meier analysis, chi-square test, and Wilcoxon's rank-sum., Results: From September 7, 2020 to February 28, 2022, 215 potential DCD hearts were offered of which 98 (46%) were accepted and attended. There were 77 potential donors (36%) which proceeded to death within 2 hours, with 57 (27%) donor hearts successfully retrieved and perfused ex situ and 50 (23%) DCD hearts going on to be transplanted. During this same period, 179 DBD hearts were transplanted. Overall, there was no difference in the 30-day survival rate between DCD and DBD (94% vs 93%) or 90 day survival (90% vs 90%) respectively. There was a higher rate of ECMO use post-DCD heart transplants compared to DBD (40% vs 16%, p = 0.0006), and DCD hearts in the pre pilot era, (17%, p = 0.002). There was no difference in length of ICU stay (9 DCD vs 8 days DBD, p = 0.13) nor hospital stay (28 DCD vs 27 DBD days, p = 0.46)., Conclusion: During this pilot study, 3 specialist retrieval teams were able to retrieve DCD hearts nationally for all 7 UK heart transplant centers. DCD donors increased overall heart transplantation in the UK by 28% with equivalent early posttransplant survival compared with DBD donors., Competing Interests: Disclosure The authors have no conflicts of interest to declare. This research was funded by the National Health Service Blood and Transplant and National Health Service England., (Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

144. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update.

Author

Saeed D, Feldman D, Banayosy AE, Birks E, Blume E, Cowger J, Hayward C, Jorde U, Kremer J, MacGowan G, Maltais S, Maybaum S, Mehra M, Shah KB, Mohacsi P, Schweiger M, Schroeder SE, Shah P, Slepian M, Tops LF, Alvarez P, Arabia F, Aslam S, Benson-Louis L 4th, Birati E, Buchholz HW, Cedars A, Christensen D, Ciarka A, Coglianese E, Cogswell R, Cook J, Copeland J, Costello JG, Drakos SG, Eghtesady P, Elliot T, Estep JD, Eulert-Grehn JJ, Fabrizio R, Garbade J, Gelow J, Guglin M, Hernandez-Montfort J, Horstmanshof D, John R, Kanwar M, Khaliel F, Kim G, Kumar S, Lavee J, Leache M, Leprince P, Lim S, Loforte A, Maly J, Najjar S, Netuka I, Pamboukian SV, Patel SR, Pinney S, Pluym CV, Potapov E, Robson D, Rochlani Y, Russell S, Sandau K, Sandoval E, Sayer G, Schettle S, Schibilsky D, Schlöglhofer T, Schmitto J, Siddique A, Silvestry S, Slaughter MS, Sun B, Takayama H, Tedford R, Teuteberg JJ, Ton VK, Uriel N, Vierecke J, Zimpfer D, and D'Alessandro D

Subjects
Humans, Heart, Lung Transplantation, Heart Transplantation, Heart-Assist Devices, Heart Failure surgery
Published
2023
Full Text
View/download PDF

145. Ventricular assist devices in transposition and failing systemic right ventricle: role of tricuspid valve replacement.

Author

Gonzalez-Fernandez O, De Rita F, Coats L, Crossland D, Nassar MS, Hermuzi A, Santos Lopes B, Woods A, Robinson-Smith N, Petit T, Seller N, O'Sullivan J, McDiarmid A, Schueler S, Hasan A, MacGowan G, and Jansen K

Subjects
Adult, Heart Ventricles diagnostic imaging, Heart Ventricles surgery, Humans, Retrospective Studies, Treatment Outcome, Tricuspid Valve diagnostic imaging, Tricuspid Valve surgery, Heart Failure, Heart-Assist Devices, Transposition of Great Vessels, Tricuspid Valve Insufficiency complications
Abstract

Objectives: Ventricular assist device (VAD) for systemic right ventricular (RV) failure patients post-atrial switch, for transposition of the great arteries (TGA), and those with congenitally corrected TGA has proven useful to reduce transpulmonary gradient and bridge-to-transplantation. The purpose of this study is to describe our experience of VAD in systemic RV failure and our move towards concomitant tricuspid valve replacement (TVR)., Methods: This is a single-centre retrospective study of consecutive adult patients receiving HeartWare VAD for systemic RV failure between 2010 and 2019. From 2017, concomitant TVR was performed routinely. Demographic, clinical variables and echocardiographic and haemodynamic measurements pre- and post-VAD implantation were recorded. Complications on support, heart transplantation and survival rates were described., Results: Eighteen patients underwent VAD implantation. Moderate or severe systemic tricuspid regurgitation was present in 83.3% of patients, and subpulmonic left ventricular impairment in 88.9%. One-year survival was 72.2%. VAD implantation was technically feasible and successful in all but one. Post-VAD, transpulmonary gradient fell from 16 (15-22) to 10 (7-13) mmHg (P = 0.01). Patients with TVR (n = 6) also demonstrated a reduction in mean pulmonary and wedge pressures. Furthermore, subpulmonic left ventricular end-diastolic dimension (44.3 vs 39.6 mm; P = 0.03) and function improved in this group. After 1 year of support, 72.2% of patients were suitable for transplantation., Conclusions: VAD is an effective strategy as bridge-to-candidacy and bridge-to-transplantation in patients with end-stage systemic RV failure. Concomitant TVR at the time of implant is associated with better early haemodynamic and echocardiographic results post-VAD., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.)

Published
2022
Full Text
View/download PDF

146. Frailty and quality of life after invasive management for non-ST elevation acute coronary syndrome.

Author

Beska B, Coakley D, MacGowan G, Adams-Hall J, Wilkinson C, and Kunadian V

Subjects
Aged, Aged, 80 and over, Female, Frail Elderly, Geriatric Assessment, Humans, Longitudinal Studies, Male, Quality of Life, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome therapy, Frailty diagnosis
Abstract

Objective: Older patients presenting with non-ST elevation acute coronary syndrome (NSTEACS) require holistic assessment. We carried out a longitudinal cohort study to investigate health-related quality of life (HRQoL) of older, frail adults with NSTEACS undergoing coronary angiography., Methods: 217 consecutive patients aged ≥65 years (mean age 80.9±4.0 years, 60.8% male) with NSTEACS referred for coronary angiography were recruited from two tertiary cardiac centres between November 2012 and December 2015. Frailty was assessed with the Fried Frailty Index; a score of 0 was characterised as robust, 1-2 prefrail and ≥3 frail. The Short Form Survey 36 (SF-36), an HRQoL tool consisting of eight domains spanning physical and mental health, was performed at baseline and 1 year., Results: 186 patients (85.7%) had invasive revascularisation. At baseline, 52 (23.9%) patients were frail and 121 (55.8%) were prefrail, with most SF-36 domains falling below the norm-population mean. Patients with frailty had lower mean scores in all physical SF-36 domains (p≤0.05) compared with those without frailty. Robust patients had temporal improvement in two domains (role physical +5.80 (95% CI 1.31 to 10.3) and role emotional +6.46 (95% CI 1.02 to 11.9)) versus patients with frailty and prefrailty, who had a collective improvement in a greater number of physical and psychological domains at 1 year (2 domains vs 11 domains), notably role physical (prefrail +6.53 (95% CI 3.85 to 9.20) and frail +10.4 (95% CI 6.7814.1))., Conclusions: Frail older adults with NSTEACS have poor HRQoL. One year following invasive management, there are modest improvements in HRQoL, most marked in frail and prefrail patients, who received a proportionally larger benefit than robust patients., Trial Registration Number: NCT01933581., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2022
Full Text
View/download PDF

147. Association between cardiac high-energy phosphate metabolism and whole body metabolism in healthy female adults.

Author

Wibowo PG, Charman SJ, Okwose NC, Velicki L, Popovic D, Hollingsworth KG, Macgowan GA, and Jakovljevic DG

Subjects
Adiposity, Adult, Aged, Aging, Blood Glucose analysis, Body Mass Index, Exercise, Female, Humans, Middle Aged, Oxygen Consumption, Adenosine Triphosphate metabolism, Metabolism physiology, Myocardium metabolism, Phosphocreatine metabolism
Abstract

Decline in cardiac high-energy phosphate metabolism [phosphocreatine-to-ATP (PCr/ATP) ratio] and whole body metabolism increase the risk of heart failure and metabolic diseases. The aim of the present study was to assess the relationship between PCr/ATP ratio and measures of body metabolic function. A total of 35 healthy women (56+/-14.0 years of age) underwent cardiac 31P magnetic resonance spectroscopy to assess PCr/ATP ratio - an index of cardiac high-energy phosphate metabolism. Fasting and 2-hour glucose levels were assessed using oral glucose tolerance test. Indirect calorimetry was performed to determine oxygen consumption and resting metabolic rate. There were no significant relationships between PCr/ATP ratio and resting metabolic rate (r=-0.09, p=0.62), oxygen consumption (r=-0.11, p=0.54), fasting glucose levels (r=-0.31, p=0.07), and 2-hour plasma glucose (r=-0.10, p=0.58). Adjusted analysis for covariates including age, body mass index, fat mass, and physical activity, had no significant influence on the relationship between PCr/ATP ratio and body metabolism. In conclusion, the lack of relationship between cardiac PCr/ATP ratio, glucose control and metabolic rate may suggest that overall metabolic function does not influence cardiac high-energy phosphate metabolism.

Published
2021
Full Text
View/download PDF

148. Markers of Right Ventricular Dysfunction Predict Maximal Exercise Capacity After Left Ventricular Assist Device Implantation.

Author

Bouzas-Cruz N, Koshy A, Gonzalez-Fernandez O, Ferrera C, Green T, Okwose NC, Woods A, Tovey S, Robinson-Smith N, Mcdiarmid AK, Parry G, Gonzalez-Juanatey JR, Schueler S, Jakovljevic DG, and Macgowan G

Subjects
Adult, Female, Heart Failure physiopathology, Humans, Male, Middle Aged, Prospective Studies, Exercise Tolerance physiology, Heart Failure surgery, Heart-Assist Devices, Ventricular Dysfunction, Right physiopathology
Abstract

Although left ventricular assist device (LVAD) improves functional capacity, on average LVAD patients are unable to achieve the aerobic capacity of normal healthy subjects or mild heart failure patients. The aim of this study was to examine if markers of right ventricular (RV) function influence maximal exercise capacity. This was a single-center prospective study that enrolled 20 consecutive HeartWare ventricular assist device patients who were admitted at the Freeman Hospital (Newcastle upon Tyne, United Kingdom) for a heart transplant assessment from August 2017 to October 2018. Mean peak oxygen consumption (Peak VO2) was 14.0 ± 5.0 ml/kg/min, and mean peak age and gender-adjusted percent predicted oxygen consumption (%VO2) was 40.0% ± 11.5%. Patients were subdivided into two groups based on the median peak VO2, so each group consisted of 10 patients (50%). Right-sided and pulmonary pressures were consistently higher in the group with poorer exercise tolerance. Patients with poor exercise tolerance (peak VO2 below the median) had higher right atrial pressures at rest (10.6 ± 6.4 vs. 4.3 mmHg ± 3.2; p = 0.02) and the increase with passive leg raising was significantly greater than those with preserved exercise tolerance (peak VO2 above the median). Patients with poor functional capacity also had greater RV dimensions (4.4 cm ± 0.5 vs. 3.7 cm ± 0.5; p = 0.02) and a higher incidence of significant tricuspid regurgitation (moderate or severe tricuspid regurgitation in five patients in the poor exercise capacity group vs. none in the preserved exercise capacity group; p = 0.03). In conclusion, echocardiographic and hemodynamic markers of RV dysfunction discriminate between preserved and nonpreserved exercise capacity in HeartWare ventricular assist device patients., Competing Interests: Disclosure: The authors have no conflicts of interest to report., (Copyright © ASAIO 2020.)

Published
2021
Full Text
View/download PDF

149. Impact of donor variables on heart transplantation outcomes in mechanically bridged versus standard recipients†.

Author

Urban M, Booth K, Jungschleger J, Netuka I, Schueler S, and MacGowan G

Subjects
Adult, Donor Selection, Europe epidemiology, Female, Heart Transplantation mortality, Humans, Male, Middle Aged, Prospective Studies, Survival Rate trends, Treatment Outcome, United States epidemiology, Young Adult, Heart Diseases surgery, Heart Transplantation methods, Heart-Assist Devices, Registries, Tissue Donors statistics & numerical data, Transplant Recipients
Abstract

Objectives: This study aimed to quantify the impact of donor variables on post-heart transplantation mortality and morbidity in recipients with and without a pretransplant left ventricular assist device (LVAD)., Methods: This is a prospective cohort study of the ISHLT Transplant Registry that includes all primary heart transplants in adult recipients (January 2005-June 2013, n = 15 532). All recipients were divided into patients with a durable continuous-flow LVAD (LVAD recipient, n = 3315) and without mechanical support (standard recipient, n = 12 217). Donors were classified as high risk (n = 3751) and low risk (n = 11 781). Transplants were categorized into low-risk donor/standard recipient (n = 9214), high-risk donor/standard recipient (n = 3003), low-risk donor/LVAD recipient (n = 2567) and high-risk donor/LVAD recipient (n = 748). Outcomes prior to discharge, survival at 5 years and freedom from complications were computed for each group., Results: LVAD recipients experienced more episodes of infection, stroke and acute rejection with both low- (P < 0.001, P < 0.001, P < 0.001) and high-risk donors (P < 0.001, P = 0.008, P = 0.028) prior to transplant discharge. Within standard recipients, a higher rate of primary graft failure (P = 0.035), infection (P = 0.001), dialysis (P = 0.012), acute rejection (P = 0.037) and less freedom from cardiac allograft vasculopathy (P < 0.001) and malignancy (P = 0.004) was observed with high-risk donors. Within LVAD recipients, no differences in complications prior to discharge or long-term morbidity were detected between low- and high-risk donors. When compared to standard recipient/low-risk donors, all the 3 remaining categories had an increased probability of death or graft failure within 90 days: LVAD recipient/low-risk donor [hazard ratio (HR) 1.26, confidence interval (CI) 1.05-1.51; P = 0.012], standard recipient/high-risk donor (HR 1.47, CI 1.27-1.71; P < 0.001) and LVAD recipient/high-risk donor (HR 1.72, CI 1.32-2.24; P < 0.001). Between 90 days and 5 years, only standard recipient/high-risk donor had an increased probability of death or graft failure (HR 1.140, CI 1.020-1.274; P = 0.021) when compared to standard recipient/low-risk donor., Conclusions: LVAD recipients, whether with high- or low-risk donors, have worse early (but not late) survival and more early complications than those of standard recipients. We found that adverse donor characteristics are less predictive for determining the outcome of LVAD-bridged recipients than standard recipients., (© The Author(s) 2018. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.)

Published
2019
Full Text
View/download PDF

150. Reproducibility of Inert Gas Rebreathing Method to Estimate Cardiac Output at Rest and During Cardiopulmonary Exercise Stress Testing.

Author

Okwose NC, Zhang J, Chowdhury S, Houghton D, Ninkovic S, Jakovljević S, Jevtic B, Ropret R, Eggett C, Bates M, MacGowan G, and Jakovljevic D

Subjects
Adult, Breath Tests, Female, Humans, Male, Noble Gases, Pulmonary Gas Exchange, Reproducibility of Results, Rest, Stroke Volume, Young Adult, Cardiac Output, Exercise Test
Abstract

The present study evaluated reproducibility of the inert gas rebreathing method to estimate cardiac output at rest and during cardiopulmonary exercise testing. Thirteen healthy subjects (10 males, 3 females, ages 23-32 years) performed maximal graded cardiopulmonary exercise stress test using a cycle ergometer on 2 occasions (Test 1 and Test 2). Participants cycled at 30-watts/3-min increments until peak exercise. Hemodynamic variables were assessed at rest and during different exercise intensities (i. e., 60, 120, 150, 180 watts) using an inert gas rebreathing technique. Cardiac output and stroke volume were not significantly different between the 2 tests at rest 7.4 (1.6) vs. 7.1 (1.2) liters min -1 , p=0.54; 114 (28) vs. 108 (15) ml beat -1 , p=0.63) and all stages of exercise. There was a significant positive relationship between Test 1 and Test 2 cardiac outputs when data obtained at rest and during exercise were combined (r=0.95, p<0.01 with coefficient of variation of 6.0%), at rest (r=0.90, p<0.01 with coefficient of variation of 5.1%), and during exercise (r=0.89, p<0.01 with coefficient of variation 3.3%). The mean difference and upper and lower limits of agreement between repeated measures of cardiac output at rest and peak exercise were 0.4 (-1.1 to 1.8) liter min -1 and 0.5 (-2.3 to 3.3) liter min -1 , respectively. The inert gas rebreathing method demonstrates an acceptable level of test-retest reproducibility for estimating cardiac output at rest and during cardiopulmonary exercise testing at higher metabolic demands., Competing Interests: The authors declare no conflict of interest., (© Georg Thieme Verlag KG Stuttgart · New York.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results